Nordic Nanovector: Abstracts of LYMRIT 37-01 Study With Betalutin® in NHL Patients and Other Studies Accepted for Poster Presentations at ASH |
| October 02, 2018 | October 2018 Bond Updates |
|
OSLO, Norway, Oct. 2, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting data from the Phase 1/2a LYMRIT 37-01 study investigating Betalutin® (177Lu-lilotomab satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin's lymphoma (iNHL) ... |
| View more at: https://www.prnewswire.com:443/news-releases/nordic-nanovector-abstracts-of-lymrit-37-01-study-with-betalutin-in-nhl-patients-and-other-studies-accepted-for-poster-presentations-at-ash-300722511.html |
| Related News |
|